Many questions about minimal residual disease (MRD) still need to be answered for multiple myeloma (MM). Flow MRD was monitored in 104 consecutive patients with MM after induction and at the 3rd, 6th, 9th, 12th, 18th, 24th months post-transplant. Four evolution patterns were revealed: Pattern 1 had persistent MRD-negative status post-induction no progression; pattern 2 MRD-positive postinduction but became negative within 24 post-transplant; 3 positive 4 postinduction. Patients a better time...

BACKGROUND:Increasing evidence has suggested that gut flora play an important role in tumor progression and prognosis. However, the relationship between fecal microbiota hematologic malignancy requires further investigation. This study aimed to characterize of microbial community multiple myeloma (MM) patients. MATERIAL AND METHODS:A total 40 MM patients healthy controls (n=17) were retrospectively collected from First Affiliated Hospital Sun Yat-sen University October 2018 May 2019. The...

Background: Patients with multiple myeloma (MM) who have a suboptimal response to induction therapy or early relapse are classified as functional high-risk (FHR) patients and been shown dismal prognosis. The aim of this study was establish predictive nomogram for non-transplanted FHR MM. Materials Methods: group comprised 215 in our center between 1 January 2006 March 2024. To identify independent risk factors, univariate multivariate logistic regression analyses were performed, constructed...

To investigate hepatitis B virus (HBV) reactivation and survival in patients with multiple myeloma (MM) receiving bortezomib-containing regimens, we analyzed 139 MM regimens our hospital. Twenty-seven/139 were surface antigen positive (HBsAg+) nine having DNA levels > 500 IU/mL, including four 1000 IU/mL. All but five HBsAg+ treated lamivudine or entecavir before chemotherapy until at least 6 months after autologous stem cell transplant (ASCT). HBV occurred six two HBsAg- patients, who...

Abstract Background The prognostic value of 1q21 gain in newly diagnosed multiple myeloma (NDMM) remains controversial. Our aim was to investigate the a Chinese population. Materials and Methods We retrospectively identified 565 patients with NDMM from centers China. Results detected 222 (39.3%) patients, among whom 144 had three copies 1q21, 57 four 21 at least five 1q21. Copy number variation did not show any effect on disease outcome. Multivariate analysis indicated that an independent...

The aim of the present study was to verify potential association between multiple myeloma (MM) and hepatitis B/C virus (HBV/HCV) infection. This retrospective case–control trial included 299 patients with MM acute leukemia (AL). Age sex were matched two groups. B surface antigen (HBsAg) positivity rate significantly higher in group (19.4% vs. 12.0% AL; p = 0.014). HCV infection did not differ incidence cirrhosis HBsAg+ (17.2% 6.2% HBsAg− patients; 0.011). E (HEV) also (5.2% 0.4% 0.025)....

Abstract Purpose This study aimed to assess the health‐related quality of life (HRQOL) Chinese patients with different stages multiple myeloma (MM) who received various treatments and identify factors associated a lower in China. Methods A cross‐sectional, anonymous questionnaire was distributed adults MM. The measures included European Organization for Research Treatment Cancer (EORTC) (QLQ)‐C30, QLQ‐myeloma‐specific module 20 (MY20), EuroQoL EQ‐5D. data, including patient factors,...

Bortezomib is effective in the therapy of multiple myeloma (MM), but causes infections that are different from those associated with conventional chemotherapy. It important to identify risk factors facilitate bortezomib therapy. In present report, we sought (1) define features this and (2) immune mechanisms responsible for observed susceptibility these infections. We first retrospectively analyzed clinical data 143 patients who had received MM. then prospectively assessed modulation T...

Abstract RUNX2 is a transcription factor that participates in osteoblast differentiation and chondrocyte maturation plays an important role the invasion metastasis of cancers. With deepening research, evidence has indicated correlation between bone destruction However, mechanisms underlying its multiple myeloma remain unclear. By observing induction effects conditioned medium from cells on preosteoblasts (MC3T3-E1) preosteoclasts (RAW264.7) constructing myeloma-bearing mice, we found...

The green tea constituent, (-)-epigallocatechin-3-gallate (EGCG), has chemopreventive and anticancer effects. This is partially because of the selective ability EGCG to induce apoptosis death in cancer cells without affecting normal cells. In present study, activity against myeloma cell line, KM3, was examined. Our results demonstrated, for first time, that treatment KM3 line with inhibits proliferation induces apoptosis, there a synergistic effect when bortezomib are combined. Further...

// Ying Li 1 , Junru Liu Beihui Huang Meilan Chen Xiangwen Diao and Juan Department of Hematology The First Affiliated Hospital Sun Yat-sen University, Guangzhou, Guangdong, China Correspondence to: Li, email: Keywords : multiple myeloma, PET/CT, treatment response Received February 02, 2016 Accepted August 13, Published 19, Abstract Multiple myeloma (MM) causes osteolytic lesions which can be detected by 18F-fluorodeoxyglucose positron emission tomography/Computed tomography (18F-FDG...

Background: Secondary primary malignancies (SPM) have attracted increasing attention with the application of autologous hematopoietic stem cell transplantation (ASCT) and novel agents in multiple myeloma (MM). acute lymphoblastic leukemia (sALL) has rarely been reported, clinical characteristics prognosis sALL not described detail. Methods: We retrospectively enrolled 179 consecutive newly diagnosed (NDMM) patients undergoing bortezomib-based induction regimens followed by upfront ASCT...

Summary The presence of transient abnormal protein banding (M‐protein immune reconstitution) in serum immunofixation electrophoresis after autologous haematopoietic stem cell transplantation patients with multiple myeloma has been reported. purpose this study was to investigate the impact post‐transplant M‐protein reconstitution on prognosis myeloma. observed 25.9% (75/290) patients. CR rate and MRD negativity were higher group (85.3% vs. 69.3%, p = 0.013, 81.9% 66.5%, 0.014). Although there...

Abstract High-dose cyclophosphamide (HD-Cy) (3 g/m 2 ) plus granulocyte colony-stimulating factor (G-CSF) is a very effective regimen for peripheral blood stem cell (PBSC) mobilization. Unfortunately, it associated with an increased risk of neutropenic fever (NF). We analyzed the effect NF on PBSC apheresis results and efficacy prophylactic antibiotics prevention HD-Cy G-CSF mobilization in patients newly diagnosed multiple myeloma (MM). First, were divided into ( +) −) groups according to...

Bendamustine is a bifunctional alkylating agent with some efficacy in the treatment of newly diagnosed and relapsed/refractory multiple myeloma (MM). Everolimus, an mammalian target rapamycin (mTOR) inhibitor, additional promising chemotherapeutic that has variety cancers. We investigated individual combinational cytotoxic effects these drugs MM cell lines (RPMI8226 MM1.S) primary cells. Our results demonstrated synergistic effect drugs, which was effective for both p53-wild-type...

Angiogenesis is an essential factor in the growth and progression of hematological malignancies including multiple myeloma (MM).Vascular endothelial its receptors have been shown to be targets for treating tumors.This study explores effect adenovirus-mediated delivery soluble vascular receptor Fms-like tyrosine kinase-1 (sFLT-1) on MM cell line KM3 nude mice.sFLT-1 cDNA was amplified by reverse transcription-polymerase chain reaction from human umbilical vein cells used as a transgene...

The purposes of this study were to evaluate the infection by hepatitis B virus (HBV) and its impact on survival provide a clinical reference for monitoring treating HBV during after autologous hematopoietic stem cell transplantation (ASCT) in patients with multiple myeloma (MM). A retrospective analysis infections was performed 70 MM who received sequential bortezomib-containing induction therapy ASCT our department from June 2006 February 2012. Among study, 11 cases (15.7 %) surface antigen...

Objective-To investigate cystathionine β synthase (CBS)/hydrogen sulfide (H2S) signaling in multiple myeloma (MM) patients and to identify its effect on the proliferation of U266 cells. Methods-Bone marrow samples 19 MM 23 healthy donors were collected. qRT-PCR was performed measure mRNA expression levels H2S synthases, synthase, γ lyase. ELISA assays quantified amount produced by two enzymes CBS CSE. CCK-8 experiment used influence inhibitor amino oxyacetic acid CSE propargylglycine Flow...

In the new therapeutic era, comparisons between regimens containing lenalidomide and bortezomib are needed.In this single-center, prospective study, patients received four to six cycles of lenalidomide+liposomal doxorubicin+dexamethasone (RAD) or bortezomib+liposomal (PAD) every 4 weeks, with subsequent autologous stem cell transplantation (ASCT) maintenance therapy. We compared efficacy, safety, patients' quality life, doctors' occupational stress RAD PAD induction in newly diagnosed MM...

Megaloblastic anemia (MA) patients often exhibit hemolysis, but it is not clear whether there are other hemolytic mechanisms in addition to intramedullary hemolysis. We retrospectively analyzed the clinical characteristics of 124 MA patients, measured erythrocyte physical parameters two with hemolysis and one healthy volunteer by atomic force microscopy, 18F-FDG uptake patient In multivariate analysis, was associated mean corpuscular volume (MCV) indirect bilirubin. A receiver operating...

Purpose Proteasome inhibition with bortezomib eliminates multiple myeloma (MM) cells by partly disrupting unfolded protein response (UPR). However, the development of drug resistance limits its utility and mechanism remains controversial. We aimed to investigate role IRE1α/Xbp-1 mediated branch UPR in resistance. Methods The expression level Xbp-1s was measured 4 MM cell lines correlated sensitivity bortezomib. LP1 MY5 different were treated bortezomib; then pivotal regulators compared...

Abstract Background To evaluate the efficacy and safety of recombinant human thrombopoietin (rhTPO) for hematopoietic reconstitution after autologous stem cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (NDMM). Method Thirty‐five cases NDMM had been enrolled into a prospective clinical trial from March 2014. The was compared between these 35 (rhTPO group) 98 historic not receiving rhTPO (control reinfusion. Results (100%) achieved both neutrophil platelet engraftment...

In order to ascertain clinical characteristics and outcomes of CD20 + multiple myeloma (MM) patients, we retrospectively analyzed 331 newly diagnosed patients with in our center. The characteristics, cell morphology, immunophenotype, cytogenetic were different between the - group. median course treatment < nCR (near complete recovery) 4.5 CD20+ group 2 Excluding IgD type, overall survival (OS) progression-free (PFS) higher than that There no statistically significant differences PFS OS after...